about
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaCatch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesBispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaElimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Chemically Programmed Bispecific Antibodies in Diabody Format.NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Emerging Opportunities and Challenges in Cancer Immunotherapy.The current status of immunotherapy in peritoneal carcinomatosis.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Acute Myeloid Leukemia: How Do We Measure Success?Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infectionInotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.Emerging biological therapies to treat acute lymphoblastic leukemia.The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Novel therapy for childhood acute lymphoblastic leukemia.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumorsBiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.Predictors of responses to immune checkpoint blockade in advanced melanomaIn Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy.Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data.Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.Agents in Development for Childhood Acute Lymphoblastic Leukemia.Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia.Bispecific antibodies in cancer immunotherapy.A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.Blinatumomab bridges the gap between leukemia and immunity.Cytokine release syndrome.Therapeutic applications of genetic code expansionOptimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in and Evaluation of Antitumor Activity In Vivo
P2860
Q26744280-9E37F4B5-D764-4697-A7CF-A1884CC9DA83Q28072131-5488196B-871A-4BAC-A863-E3DFE7754D95Q34548319-68444803-287E-484D-96B9-AEB3A71B9EA6Q36387028-DCEE9BB4-9873-4D6F-8322-EEA55088A88EQ37325019-2006B8F8-EE0C-4422-9A43-B028E72864D2Q37499526-C01715E4-266A-425E-8F17-F2F8C1A31293Q37517482-D566E0CF-7959-4F16-9973-B015D4442B66Q38436973-9D318DD9-C382-49CA-A8B1-4BAD9FF2EB64Q38788557-7A730159-472D-461A-B051-23241C6890B3Q38803361-E2762DA4-73B9-47A9-A25E-EA8CBCE09E51Q38809772-CE619113-A82E-4350-8587-3EA0FEC6789BQ38830852-1D1A9DCB-A76A-40B3-8A33-AB07B7B7E698Q38929801-44214340-D792-4E94-8E48-5E7F4073A4C4Q38948650-B447822C-401E-48D3-ABD3-BB3486FC1A81Q38977425-07AF2DD0-4ECA-48BD-ADF1-94E708223FF5Q38984055-DB2218E9-910C-4C32-8BE8-C589C5696ED3Q39002036-90C05D1D-1068-4FB8-BDF2-925831807500Q39100049-DAB48269-DFE0-43DA-8554-C1BFB3985DEEQ39128240-1DE7B86F-99C1-4965-9167-DBB5CDBB14EBQ39368957-B6AE67F2-2516-4D86-87E7-C9E6AB5916B4Q39381251-E180EE88-D880-45C1-A77A-6695E7C43C34Q40152125-705CD0DA-86D5-43F0-8A4F-FCA4F96E6A3FQ40396529-FC00C421-B168-4DC4-A5C6-04F96D1F2181Q40994161-315B71C2-48DB-4625-A832-88EB1F05C5CAQ41302727-1E105E9F-E32E-4189-B831-94421E7DE6C4Q41592942-E7D72F7C-540C-4278-98A1-385575DA750EQ41701241-1A092F43-21F5-4066-B91D-EC0FE9153CE8Q41919495-4893B26F-0AAD-43D7-87BD-BECD9B97AC03Q46474224-88B28A6E-8622-4927-8515-CF96015B1505Q47610511-28D7D843-822E-4C9A-860F-AC436A5BA016Q47634136-4B70A0F4-78F9-4B5A-B166-454C944C549FQ47767201-2A78CA6F-E210-4317-BA3E-B2DE0FB723CAQ47837260-F4380A5F-1865-4CBC-9EE0-B28CC341C5E6Q50043284-548C12B4-7F4C-44F5-A501-2AC7D0F70BBFQ51309023-D194A12C-4D71-4285-9A75-F8B1EFA08F83Q52716114-5A16F5CF-37DC-428B-A6FE-279958F32198Q52780150-8019FFC8-BD2D-4212-A46C-F9A09D54B6AAQ55438228-3913D8C8-13C2-40D2-B82F-635DD7EB4789Q57818219-AD7306B3-BAA4-412A-B3FC-4ABEB1124C62Q59138239-48D45BA4-9367-486D-99E7-FE625AE48022
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
FDA Approval: Blinatumomab.
@ast
FDA Approval: Blinatumomab.
@en
type
label
FDA Approval: Blinatumomab.
@ast
FDA Approval: Blinatumomab.
@en
prefLabel
FDA Approval: Blinatumomab.
@ast
FDA Approval: Blinatumomab.
@en
P2093
P1476
FDA Approval: Blinatumomab.
@en
P2093
Albert Deisseroth
Ann T Farrell
Brenda J Gehrke
Candace Gomez-Broughton
Carolyn L Yancey
Chia-Wen Ko
Deborah Schmiel
Donna Przepiorka
Haw-Jyh Chiu
Nitin Mehrotra
P304
P356
10.1158/1078-0432.CCR-15-0612
P407
P577
2015-09-01T00:00:00Z